Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Récher C, Dumas PY, Bérard E, Tavitian S, Leguay T, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Luquet I, Klein E, de Grande AC, Sarry A, Zukunft S, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M, Serve H, Bertoli S, Pigneux A, Röllig C. Récher C, et al. Among authors: vial jp. Am J Hematol. 2025 Jan;100(1):23-32. doi: 10.1002/ajh.27510. Epub 2024 Nov 18. Am J Hematol. 2025. PMID: 39555737 Free PMC article.
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C, Largeaud L, Bertoli S. Gondran C, et al. Among authors: vial jp. Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Bertoli S, et al. Among authors: vial jp. Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773. Cancers (Basel). 2020. PMID: 32218221 Free PMC article.
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Dumas PY, Bertoli S, Bérard E, Largeaud L, Bidet A, Delabesse E, Leguay T, Leroy H, Gadaud N, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C. Dumas PY, et al. Among authors: vial jp. Cancers (Basel). 2020 Jul 24;12(8):2044. doi: 10.3390/cancers12082044. Cancers (Basel). 2020. PMID: 32722211 Free PMC article.
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.
Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Dumas PY, et al. Among authors: vial jp. Blood Adv. 2020 Aug 25;4(16):3840-3849. doi: 10.1182/bloodadvances.2020002511. Blood Adv. 2020. PMID: 32790847 Free PMC article.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: vial jp. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Leroy H, Gadaud N, Bérard E, Klein E, Luquet I, Vial JP, Rieu JB, Lechevalier N, Tavitian S, Leguay T, Largeaud L, Bidet A, Delabesse E, Sarry A, de Grande AC, Récher C, Pigneux A, Bertoli S, Dumas PY. Leroy H, et al. Among authors: vial jp. Cancer Med. 2024 Feb;13(3):e7003. doi: 10.1002/cam4.7003. Cancer Med. 2024. PMID: 38400682 Free PMC article.
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.
Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau ML, Rieu JB, Tavitian S, Huguet F, Picard M, Bories P, Vial JP, Lechevalier N, Béné MC, Luquet I, Mansat-De Mas V, Delabesse E, Récher C, Vergez F. Canali A, et al. Among authors: vial jp. Clin Cancer Res. 2023 Jan 4;29(1):134-142. doi: 10.1158/1078-0432.CCR-22-2237. Clin Cancer Res. 2023. PMID: 36318706
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.
Vergez F, Largeaud L, Bertoli S, Nicolau ML, Rieu JB, Vergnolle I, Saland E, Sarry A, Tavitian S, Huguet F, Picard M, Vial JP, Lechevalier N, Bidet A, Dumas PY, Pigneux A, Luquet I, Mansat-De Mas V, Delabesse E, Carroll M, Danet-Desnoyers G, Sarry JE, Récher C. Vergez F, et al. Among authors: vial jp. Blood Cancer J. 2022 Aug 16;12(8):117. doi: 10.1038/s41408-022-00712-7. Blood Cancer J. 2022. PMID: 35973983 Free PMC article.
35 results